摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[(2R,3S)-3-(dibenzylamino)-2-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)(4-methylamino-3-nitrophenyl)sulfonamide | 602311-75-1

中文名称
——
中文别名
——
英文名称
N-[(2R,3S)-3-(dibenzylamino)-2-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)(4-methylamino-3-nitrophenyl)sulfonamide
英文别名
N-[(2R,3S)-3-(dibenzylamino)-2-hydroxy-4-phenylbutyl]-4-(methylamino)-N-(2-methylpropyl)-3-nitrobenzenesulfonamide
N-[(2R,3S)-3-(dibenzylamino)-2-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)(4-methylamino-3-nitrophenyl)sulfonamide化学式
CAS
602311-75-1
化学式
C35H42N4O5S
mdl
——
分子量
630.808
InChiKey
VNXADFPMGMEDOW-OIDHKYIRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    7.2
  • 重原子数:
    45
  • 可旋转键数:
    15
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    127
  • 氢给体数:
    2
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] BROADSPECTRUM SUBSTITUTED BENZIMIDAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS
    [FR] INHIBITEURS DE PROTEASE DE VIH A BASE DE BENZIMIDAZOLE SULFONAMIDE SUBSTITUES A LARGE SPECTRE
    摘要:
    本发明涉及具有以下式(I)的化合物,其中N-氧化物,盐,立体异构体形式,消旋混合物,前药,酯及其代谢物,其中R1和R8各自为H,可选择地取代的C1-6烷基,C2-6烯基,C3-7环烷基,芳基,Het1,Het2;R1也可以是具有式(R11aR11b)NC(R10aRl0b)CR9-的基团;t为0、1或2;R2为H或C1-6烷基;L为-C(=O)-,-O-C(=O)-,-NR8-C(=O)-,-O-C1-6烷二基-C(=O)-,-NR8-C1-6烷二基-C(=O)-,-S(=O)2-,-O-S(=O)2-,-NR8-S(=O)2;R3为C1-6烷基,芳基,C3-7环烷基,C3-7环烷基C1-4烷基,或芳基C1-4烷基;R4为H,C1-4烷基OC(=O),羧基,氨基C(=O),单或双(C1-4烷基)氨基C(=O),C3-7环烷基,C2-6烯基,C2-6炔基或可选择地取代的C1-6烷基;A为C1-6烷二基,-C(=O)-,-C(=S)-,-S(=O)2-,C1-6烷二基-C(=O)-,C1-6烷二基-C(=S)-或C1-6烷二基-S(=O)2-;R5为H,OH,C1-6烷基,Het1C1-6烷基,Het2C1-6烷基,可选择地取代的氨基-C1-6烷基;R6为C1-6烷氧,Het1,Het1O,Het2,Het2O,芳基,芳基O,C1-6烷氧基羰基氨基或氨基;如果A-不是C1-6烷二基,则R6也可以是C1-6烷基,Het1C1-4烷基,Het1OC1-4烷基,Het2C1-4烷基,Het2OC1-4烷基,芳基C1-4烷基,芳基OC1-4烷基或氨基C1-4烷基;在R6的定义中,每个氨基也可以选择性地被取代;R5和A-R6连同它们连接的氮原子一起也可以形成Het1或Het2,R12为H,-NH2,A-NR5AR6,-C1-6烷基或烷基-W-R14,其中所述烷基可选择性地用卤素,羟基,芳基,杂环芳基,Het1,Het2或氨基取代,其中所述氨基可选择性地单取代或双取代为C1-4烷基,R13为H,C1-6-烷基,可选择地被芳基,Het1,Het2,羟基,卤素,氨基取代,其中所述氨基可选择性地单取代或双取代为C1-4烷基。
    公开号:
    WO2003076413A1
  • 作为产物:
    参考文献:
    名称:
    [EN] BROADSPECTRUM SUBSTITUTED BENZIMIDAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS
    [FR] INHIBITEURS DE PROTEASE DE VIH A BASE DE BENZIMIDAZOLE SULFONAMIDE SUBSTITUES A LARGE SPECTRE
    摘要:
    本发明涉及具有以下式(I)的化合物,其中N-氧化物,盐,立体异构体形式,消旋混合物,前药,酯及其代谢物,其中R1和R8各自为H,可选择地取代的C1-6烷基,C2-6烯基,C3-7环烷基,芳基,Het1,Het2;R1也可以是具有式(R11aR11b)NC(R10aRl0b)CR9-的基团;t为0、1或2;R2为H或C1-6烷基;L为-C(=O)-,-O-C(=O)-,-NR8-C(=O)-,-O-C1-6烷二基-C(=O)-,-NR8-C1-6烷二基-C(=O)-,-S(=O)2-,-O-S(=O)2-,-NR8-S(=O)2;R3为C1-6烷基,芳基,C3-7环烷基,C3-7环烷基C1-4烷基,或芳基C1-4烷基;R4为H,C1-4烷基OC(=O),羧基,氨基C(=O),单或双(C1-4烷基)氨基C(=O),C3-7环烷基,C2-6烯基,C2-6炔基或可选择地取代的C1-6烷基;A为C1-6烷二基,-C(=O)-,-C(=S)-,-S(=O)2-,C1-6烷二基-C(=O)-,C1-6烷二基-C(=S)-或C1-6烷二基-S(=O)2-;R5为H,OH,C1-6烷基,Het1C1-6烷基,Het2C1-6烷基,可选择地取代的氨基-C1-6烷基;R6为C1-6烷氧,Het1,Het1O,Het2,Het2O,芳基,芳基O,C1-6烷氧基羰基氨基或氨基;如果A-不是C1-6烷二基,则R6也可以是C1-6烷基,Het1C1-4烷基,Het1OC1-4烷基,Het2C1-4烷基,Het2OC1-4烷基,芳基C1-4烷基,芳基OC1-4烷基或氨基C1-4烷基;在R6的定义中,每个氨基也可以选择性地被取代;R5和A-R6连同它们连接的氮原子一起也可以形成Het1或Het2,R12为H,-NH2,A-NR5AR6,-C1-6烷基或烷基-W-R14,其中所述烷基可选择性地用卤素,羟基,芳基,杂环芳基,Het1,Het2或氨基取代,其中所述氨基可选择性地单取代或双取代为C1-4烷基,R13为H,C1-6-烷基,可选择地被芳基,Het1,Het2,羟基,卤素,氨基取代,其中所述氨基可选择性地单取代或双取代为C1-4烷基。
    公开号:
    WO2003076413A1
点击查看最新优质反应信息

文献信息

  • Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
    申请人:Surleraux Dominique, Louis, Nestor, Ghislain
    公开号:US20050171175A1
    公开(公告)日:2005-08-04
    The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R 1 and R 8 each are H, optionally substituted C 1-6 alkyl, C 2-6 alkenyl, C 3-7 cycloalkyl, aryl, Het 1 , Het 2 ; R 1 may also be a radical of formula (R 11a R 11b )NC(R 10a R 10b )CR 9 —; t is 0, 1 or 2; R 2 is H or C 1-6 alkyl; L is —C(═O)—, —O—C(═O)—, —NR 8 —C(═O)—, —O—C 1-6 alkanediyl-C(═O)—, —NR 8 —C 1-6 alkanediyl-C(═O)—, —S(═O) 2 —, —O—S(═O) 2 —, —NR 8 —S(═O) 2 ; R 3 is C 1-6 alkyl, aryl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, or arylC 1-4 alkyl; R 4 is H, C 1-4 alkylOC(═O), carboxyl, aminoC(═O), mono- or di(C 1-4 alkyl)aminoC(═O), C 3-7 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl or optionally substituted C 1-6 alkyl; A is C 1-6 alkanediyl, —C(═O)—, —C(═S)—, —S(═O) 2 —, C 1-6 alkanediyl-C(═O)—, C 1-6 alkanediyl-C(═S)— or C 1-6 alkanediyl-S(═O) 2 —; R 5 is H, OH, C 1-6 alkyl, Het 1 C 1-6 alkyl, Het 2 C 1-6 alkyl, optionally substituted aminoC 1-6 alkyl; R 6 is C 1-6 alkylO, Het 1 , Het 1 O, Het 2 , Het 2 O, aryl, arylO, C 1-6 alkyloxy-carbonylamino or amino; and in case -A- is other than C 1-6 alkanediyl then R 6 may also be C 1-6 alkyl, Het 1 C 1-4 alkyl, Het 1 OC 1-4 alkyl, Het 2 C 1-4 alkyl, Het 2 OC 1-4 alkyl, arylC 1-4 alkyl, arylOC 1-4 alkyl or aminoC 1-4 alkyl; whereby each of the amino groups in the definition of R 6 may optionally be substituted; R 5 and -A-R 6 taken together with the nitrogen atom to which they are attached may also form Het 1 or Het 2 ′R 12 is H, —NH 2 , —NR 5 AR 6 , —C 1-6 alkyl or alkyl-W—R 14 , wherein said alkyl is optionally substituted with halogen, hydroxy, aryl, heteroaryl, Het 1 , Het 2 , or amino wherein said amino is optionally mono- or di-substituted with C 1-4 alkyl and R 13 is H, C 1-6 -alkyl, optionally substituted by aryl, Het 1 , Het 2 , hydroxy, halogen, amino whereby the amino group may be optionally be mono- or di-substituted with C 1-4 alkyl.
    本发明涉及式如下的化合物 其 N-氧化物、盐类、立体异构体、外消旋混合物、原药、酯类和代谢物,其中 R 1 和 R 8 均为 H、任选取代的 C 1-6 烷基、C 2-6 烯基 3-7 环烷基、芳基、Het 1 、Het 2 ; R 1 也可以是式 (R 11a R 11b )NC(R 10a R 10b )CR 9 -;t 为 0、1 或 2;R 2 是 H 或 C 1-6 烷基;L 是-C(═O)-、-O-C(═O)-、-NR 8 -C(═O)-、-O-C 1-6 烷二基-C(═O)-,-NR 8 -C 1-6 烷二基-C(═O)-,-S(═O) 2 -、-O-S(═O) 2 -、-NR 8 -S(═O) 2 ; R 3 是 C 1-6 烷基、芳基、C 3-7 环烷基、C 3-7 环烷基C 1-4 烷基,或芳基C 1-4 烷基;R 4 是 H、C 1-4 烷基OC(═O)、羧基、氨基C(═O)、单-或二(C 1-4 烷基)氨基C(═O)、C 3-7 环烷基、C 2-6 烯基、C 2-6 炔基或任选取代的 C 1-6 烷基;A 是 C 1-6 烷二基、-C(═O)-、-C(═S)-、-S(═O) 2 -, C 1-6 烷二基-C(═O)-,C 1-6 烷二基-C(═S)-或 C 1-6 烷二基-S(═O) 2 -; R 5 是 H、OH、C 1-6 烷基、Het 1 C 1-6 烷基,Het 2 C 1-6 烷基、任选取代的氨基C 1-6 烷基;R 6 是 C 1-6 烷基 1 ,Het 1 O、Het 2 , Het 2 O、芳基、芳基O、C 1-6 烷氧基羰基氨基或氨基;如果 -A- 不是 C 1-6 烷二基,则 R 6 也可以是 C 1-6 烷基、Het 1 C 1-4 烷基,Het 1 OC 1-4 烷基,Het 2 C 1-4 烷基,Het 2 OC 1-4 烷基,芳基C 1-4 烷基、芳基OC 1-4 烷基或氨基C 1-4 烷基;其中 R 6 可任选被取代;R 5 和-A-R 6 与它们所连接的氮原子一起也可形成 Het 1 或 Het 2 ′R 12 是 H、-NH 2 、-NR 5 AR 6 , -C 1-6 烷基或烷基-W-R 14 其中所述烷基可任选被卤素、羟基、芳基、杂芳基、Het 1 、Het 2 或氨基,其中所述氨基可选地被 C 1-4 烷基和 R 13 是 H、C 1-6 -烷基,可选择被芳基取代,Het 1 Het 2 羟基、卤素、氨基,其中氨基可任选被 C 1-4 烷基。
  • BROADSPECTRUM SUBSTITUTED BENZIMIDAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS
    申请人:Tibotec Pharmaceuticals Ltd.
    公开号:EP1485358A1
    公开(公告)日:2004-12-15
  • SMALL MOLECULE ENTRY INHIBITORS
    申请人:Surleraux Dominique Louis
    公开号:US20090203743A1
    公开(公告)日:2009-08-13
    The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R 1 and R 8 each are H, optionally substituted C 1-6 alkyl, C 2-6 alkenyl, C 3-7 cycloalkyl, aryl, Het 1 , Het 2 ; R 1 may also be a radical of formula (R 11a R 11b )NC(R 10a R 10b )CR 9 —; t is 0, 1 or 2; R 2 is H or C 1-6 alkyl; L is —C(═O)—, —O—C(═O)—, —NR 8 —C(═O)—, —O—C 1-6 alkanediyl-C(═O)—, —NR 8 —C 1-6 alkanediyl-C(═O)—, —S(═O) 2 —, —O—S(═O) 2 —, —NR 8 —S(═O) 2 ; R 3 is C 1-6 alkyl, aryl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, or arylC 1-4 alkyl; R 4 is H, C 1-4 alkylOC(═O), carboxyl, aminoC(═O), mono- or di(C 1-4 alkyl)aminoC(═O), C 3-7 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl or optionally substituted C 1-6 alkyl; A is C 1-6 alkanediyl, —C(═O)—, —C(═S)—, —S(═O) 2 —, C 1-6 alkanediyl-C(═O)—, C 1-6 alkanediyl-C(═S)— or C 1-6 alkanediyl-S(═O) 2 —; R 5 is H, OH, C 1-6 alkyl, Het 1 C 1-6 alkyl, Het 2 C 1-6 alkyl, optionally substituted amino-C 1-6 alkyl; R 6 is C 1-6 alkylO, Het 1 , Het 1 O, Het 2 , Het 2 O, aryl, arylO, C 1-6 alkyloxy-carbonylamino or amino; and in case -A- is other than C 1-6 alkanediyl then R 6 may also be C 1-6 alkyl, Het 1 C 1-4 alkyl, Het 1 OC 1-4 alkyl, Het 2 C 1-4 alkyl, Het 2 OC 1-4 alkyl, arylC 1-4 alkyl, arylOC 1-4 alkyl or aminoC 1-4 alkyl; whereby each of the amino groups in the definition of R 6 may optionally be substituted; R 5 and -A-R 6 taken together with the nitrogen atom to which they are attached may also form Het 1 or Het 2 ′ R 12 is H, —NH 2 , —NR 5 AR 6 , —C 1-6 alkyl or alkyl-W—R 14 , wherein said alkyl is optionally substituted with halogen, hydroxy, aryl, heteroaryl, Het 1 , Het 2 , or amino wherein said amino is optionally mono- or di-substituted with C 1-4 alkyl and R 13 is H, C 1-6 -alkyl, optionally substituted by aryl, Het 1 , Het 2 , hydroxy, halogen, amino whereby the amino group may be optionally be mono- or di-substituted with C 1-4 alkyl.
  • US8143421B2
    申请人:——
    公开号:US8143421B2
    公开(公告)日:2012-03-27
  • [EN] BROADSPECTRUM SUBSTITUTED BENZIMIDAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTEASE DE VIH A BASE DE BENZIMIDAZOLE SULFONAMIDE SUBSTITUES A LARGE SPECTRE
    申请人:TIBOTEC PHARM LTD
    公开号:WO2003076413A1
    公开(公告)日:2003-09-18
    The present invention concerns the compounds having the formula (I), wherein N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aRl0b)CR9-; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is -C(=O)-, -O-C(=O)-, -NR8-C(=O)-, -O-C1-6alkanediyl-C(=O)-, -NR8-C1-6alkanediyl-C(=O)-, -S(=O)2-, -O-S(=O)2-, -NR8-S(=O)2 ; R3 is C1-6alkyl, aryl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or arylC1-4alkyl; R4 is H, C1-4alkylOC(=O), carboxyl, aminoC(=O), mono- or di(C1-4alkyl)aminoC(=O), C3-7cycloalkyl, C2-6alkenyl, C2-6alkynyl or optionally substituted C1-6alkyl; A is C1-6alkanediyl, -C(=O)-, -C(=S)-, -S(=O)2-, C1-6alkanediyl-C(=O)-, C1-6 alkanediyl-C(=S)- or C1-6alkanediyl-S(=O)2-; R5 is H, OH, C1-6alkyl, Het1C1-6alkyl, Het2C1-6 alkyl, optionally substituted amino­-C1-6alkyl; R6 is C1-6alkylO, Het1, Het1O, Het2, Het2O, aryl, arylO, C1-6 alkyloxy­carbonylamino or amino; and in case _A- is other than C1-6alkanediyl then R6 may also be C1-6alkyl, Het1C1-4alkyl, Het1OC1-4alkyl, Het2C1-4alkyl, Het2OC1-4alkyl, arylC1-4alkyl, arylOC1-4alkyl or aminoC1-4alkyl; whereby each of the amino groups in the definition of R6 may optionally be substituted; R5 and _A-R6 taken together with the nitrogen atom to which they are attached may also form Het1 or Het2, R12 , is H, - NH2, _NR5AR6, - C1-6alkyl or alkyl-W-R14 , wherein said alkyl is optionally substituted with halogen, hydroxy, aryl, heteroaryl, Het1, Het2, or amino wherein said amino is optionally mono- or di-substituted with C1-4alkyl and R13 is H, C1-6-alkyl, optionally substituted by aryl, Het1, Het2, hydroxy, halogen, amino whereby the amino group may be optionally be mono- or di-substituted with C1-4alkyl.
    本发明涉及具有以下式(I)的化合物,其中N-氧化物,盐,立体异构体形式,消旋混合物,前药,酯及其代谢物,其中R1和R8各自为H,可选择地取代的C1-6烷基,C2-6烯基,C3-7环烷基,芳基,Het1,Het2;R1也可以是具有式(R11aR11b)NC(R10aRl0b)CR9-的基团;t为0、1或2;R2为H或C1-6烷基;L为-C(=O)-,-O-C(=O)-,-NR8-C(=O)-,-O-C1-6烷二基-C(=O)-,-NR8-C1-6烷二基-C(=O)-,-S(=O)2-,-O-S(=O)2-,-NR8-S(=O)2;R3为C1-6烷基,芳基,C3-7环烷基,C3-7环烷基C1-4烷基,或芳基C1-4烷基;R4为H,C1-4烷基OC(=O),羧基,氨基C(=O),单或双(C1-4烷基)氨基C(=O),C3-7环烷基,C2-6烯基,C2-6炔基或可选择地取代的C1-6烷基;A为C1-6烷二基,-C(=O)-,-C(=S)-,-S(=O)2-,C1-6烷二基-C(=O)-,C1-6烷二基-C(=S)-或C1-6烷二基-S(=O)2-;R5为H,OH,C1-6烷基,Het1C1-6烷基,Het2C1-6烷基,可选择地取代的氨基-C1-6烷基;R6为C1-6烷氧,Het1,Het1O,Het2,Het2O,芳基,芳基O,C1-6烷氧基羰基氨基或氨基;如果A-不是C1-6烷二基,则R6也可以是C1-6烷基,Het1C1-4烷基,Het1OC1-4烷基,Het2C1-4烷基,Het2OC1-4烷基,芳基C1-4烷基,芳基OC1-4烷基或氨基C1-4烷基;在R6的定义中,每个氨基也可以选择性地被取代;R5和A-R6连同它们连接的氮原子一起也可以形成Het1或Het2,R12为H,-NH2,A-NR5AR6,-C1-6烷基或烷基-W-R14,其中所述烷基可选择性地用卤素,羟基,芳基,杂环芳基,Het1,Het2或氨基取代,其中所述氨基可选择性地单取代或双取代为C1-4烷基,R13为H,C1-6-烷基,可选择地被芳基,Het1,Het2,羟基,卤素,氨基取代,其中所述氨基可选择性地单取代或双取代为C1-4烷基。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐